[ad_1]
Multinational pharmaceutical and biotech firm Pfizer and AI-powered knowledge firm Tempus introduced a multiyear strategic alliance to make the most of AI and machine studying to tell drug discovery and growth in oncology.
Pfizer will leverage Tempus’ library of de-identified knowledge to speed up therapeutic growth in oncology. It would additionally use Tempus’ AI-driven companion diagnostic choices and medical trial-matching program to assist therapeutic analysis and growth.
“Pfizer shares our dedication to bringing novel remedies to sufferers quicker, and we look ahead to working collectively to usher within the subsequent era of oncology therapeutics,” Eric Lefkofsky, founder and CEO of Tempus, mentioned in an announcement.
“That is the third strategic collaboration Tempus has established with a world pharmaceutical chief within the final 12 months, as we imagine that combining our technological capabilities with pharma’s deep R&D experience will get us a lot nearer in realizing the total potential of precision medication.”
THE LARGER TREND
Tempus is not any stranger to partnering with pharma giants for oncology care.
Final 12 months, the corporate announced a three-year agreement with British multinational pharmaceutical and biotech firm GSK, which included a $70 million preliminary fee to speed up drug discovery in oncology, establish drug targets, enhance its medical trial design and velocity up trial enrollment.
The Chicago-based firm additionally announced a collaboration with American pharma firm Eli Lilly to broaden entry to genomic testing for sufferers with superior/metastatic non-small cell lung most cancers.
In 2021, Tempus announced a strategic collaboration with British-Swedish multinational pharmaceutical and biotechnology firm AstraZeneca to advance drug discovery and growth in oncology.
Final 12 months, the corporate introduced that it had scored $275 million in funding by a mix of debt financing and fairness from current buyers, bringing its complete increase to $1.3 billion.
Different gamers using AI for drug discovery in oncology embrace AI-enabled pathology firm PathAI and tech firm Exscientia.
[ad_2]
Source link
